Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today

Trading on Aktietorget.

Trading in SynAct Pharma AB’s shares and series TO 1 subscription options begins today on Aktietorget. The shares are traded under the trading code ”SYNACT” ad and have an ISIN code SE0008241491. Series TO 1 subscription options are traded under the trading code ”SYNACT TO 1” and have an ISIN code SE0008320972.

Summary of terms and conditions for series TO 1 subscription options

Possession of a series TO 1 subscription option entitles the holder to subscribe for a newly issued share at a rate of SEK 6.40 per share. Subscription to shares with the support of series TO 1 subscription options may take place from 9 March 2017 until 23 March 2017.

Financial advisor

Sedermera Fondkommission is acting as financial advisor to SynAct Pharma AB in connection with the listing.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: joo@synactpharma.com

Henrik Stage
CFO, SynAct Pharma AB
Telephone: +45 40 26 09 00
E-mail: hs@synactpharma.com

SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.